drugset / Trial / NCT06559644
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of autologous tumor-specific T cells, known as Hema-NeoTIL0 in treating relapsed/refractory B-ALL/AML.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hema-NeoTIL01 | Cell therapy | 2e+07 cells/kg | Intravenous |
| Subject | Hema-NeoTIL01 | Cell therapy | 6e+07 cells/kg | Intravenous |
| Subject | Hema-NeoTIL01 | Cell therapy | 2e+08 cells/kg | Intravenous |